196 related articles for article (PubMed ID: 1336343)
1. In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia.
Azoulay-Dupuis E; Vallee E; Veber B; Bedos JP; Bauchet J; Pocidalo JJ
Antimicrob Agents Chemother; 1992 Dec; 36(12):2698-703. PubMed ID: 1336343
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model.
Bédos JP; Rieux V; Bauchet J; Muffat-Joly M; Carbon C; Azoulay-Dupuis E
Antimicrob Agents Chemother; 1998 Apr; 42(4):862-7. PubMed ID: 9559797
[TBL] [Abstract][Full Text] [Related]
3. In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoniae in a mouse pneumonia model.
Moine P; Vallée E; Azoulay-Dupuis E; Bourget P; Bédos JP; Bauchet J; Pocidalo JJ
Antimicrob Agents Chemother; 1994 Sep; 38(9):1953-8. PubMed ID: 7811003
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of BB-83698, a novel peptide deformylase inhibitor, in a mouse model of pneumococcal pneumonia.
Azoulay-Dupuis E; Mohler J; Bédos JP
Antimicrob Agents Chemother; 2004 Jan; 48(1):80-5. PubMed ID: 14693522
[TBL] [Abstract][Full Text] [Related]
5. In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model.
Otsu Y; Yanagihara K; Fukuda Y; Miyazaki Y; Tsukamoto K; Hirakata Y; Tomono K; Kadota J; Tashiro T; Murata I; Kohno S
Antimicrob Agents Chemother; 2003 Dec; 47(12):3699-703. PubMed ID: 14638468
[TBL] [Abstract][Full Text] [Related]
6. Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model.
Tateda K; Takashima K; Miyazaki H; Matsumoto T; Hatori T; Yamaguchi K
Antimicrob Agents Chemother; 1996 Jun; 40(6):1520-5. PubMed ID: 8726030
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy.
Bédos JP; Azoulay-Dupuis E; Moine P; Muffat-Joly M; Veber B; Pocidalo JJ; Vallée E
J Pharmacol Exp Ther; 1998 Jul; 286(1):29-35. PubMed ID: 9655838
[TBL] [Abstract][Full Text] [Related]
8. Antibacterial activity of AM-1155 against penicillin-resistant Streptococcus pneumoniae.
Tomizawa H; Tateda K; Miyazaki S; Yamaguchi K
J Antimicrob Chemother; 1998 Jan; 41(1):103-6. PubMed ID: 9511043
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.
Otani T; Tanaka M; Ito E; Kurosaka Y; Murakami Y; Onodera K; Akasaka T; Sato K
Antimicrob Agents Chemother; 2003 Dec; 47(12):3750-9. PubMed ID: 14638477
[TBL] [Abstract][Full Text] [Related]
10. Efficacies of cefotaxime and ceftriaxone in a mouse model of pneumonia induced by two penicillin- and cephalosporin-resistant strains of Streptococcus pneumoniae.
Sauve C; Azoulay-Dupuis E; Moine P; Darras-Joly C; Rieux V; Carbon C; Bédos JP
Antimicrob Agents Chemother; 1996 Dec; 40(12):2829-34. PubMed ID: 9124850
[TBL] [Abstract][Full Text] [Related]
11. Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease.
Azoulay-Dupuis E; Bedos JP; Vallée E; Hardy DJ; Swanson RN; Pocidalo JJ
J Infect Dis; 1991 Feb; 163(2):319-24. PubMed ID: 1988515
[TBL] [Abstract][Full Text] [Related]
12. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA
Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
[TBL] [Abstract][Full Text] [Related]
13. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.
Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1994 Sep; 38(9):2065-72. PubMed ID: 7811020
[TBL] [Abstract][Full Text] [Related]
14. Synergy between amoxicillin and gentamicin in combination against a highly penicillin-resistant and -tolerant strain of Streptococcus pneumoniae in a mouse pneumonia model.
Darras-Joly C; Bédos JP; Sauve C; Moine P; Vallée E; Carbon C; Azoulay-Dupuis E
Antimicrob Agents Chemother; 1996 Sep; 40(9):2147-51. PubMed ID: 8878597
[TBL] [Abstract][Full Text] [Related]
15. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.
Ballow CH; Jones RN; Johnson DM; Deinhart JA; Schentag JJ
Diagn Microbiol Infect Dis; 1997 Nov; 29(3):173-86. PubMed ID: 9401810
[TBL] [Abstract][Full Text] [Related]
16. Parenteral sparfloxacin compared with ceftriaxone in treatment of experimental endocarditis due to penicillin-susceptible and -resistant streptococci.
Entenza JM; Blatter M; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 1994 Dec; 38(12):2683-8. PubMed ID: 7695248
[TBL] [Abstract][Full Text] [Related]
17. Antipneumococcal activities of gemifloxacin compared to those of nine other agents.
Davies TA; Kelly LM; Pankuch GA; Credito KL; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2000 Feb; 44(2):304-10. PubMed ID: 10639354
[TBL] [Abstract][Full Text] [Related]
18. Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.
Hershberger E; Rybak MJ
Antimicrob Agents Chemother; 2000 Mar; 44(3):598-601. PubMed ID: 10681324
[TBL] [Abstract][Full Text] [Related]
19. In vivo activity and pharmacokinetics of ziracin (SCH27899), a new long-acting everninomicin antibiotic, in a murine model of penicillin-susceptible or penicillin-resistant pneumococcal pneumonia.
Wang E; Simard M; Bergeron Y; Beauchamp D; Bergeron MG
Antimicrob Agents Chemother; 2000 Apr; 44(4):1010-8. PubMed ID: 10722505
[TBL] [Abstract][Full Text] [Related]
20. Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology.
Visalli MA; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 1996 Jan; 37(1):77-84. PubMed ID: 8647777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
